A public offering of over 13 million shares of common stock has been priced by Cancer Genetics in hopes of raising $3 million in gross proceeds. The company intends to use the proceeds to pay lender fees and other costs related to the potential forbearance deals it is negotiating with banks, and to pay certain costs resulting from the termination of its deal to acquire NovellusDx.
Cancer Genetics prices $3M public offering
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.